Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;28(2):93-100.
doi: 10.1007/BF00199108.

Immunomodulatory and therapeutic properties of FK-565 in mice

J E Talmadge  1 , B Lenz, M Schneider, H Phillips, C Long
Affiliations

Immunomodulatory and therapeutic properties of FK-565 in mice

J E Talmadge et al. Cancer Immunol Immunother. 1989.

Abstract

The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Adam A, Lederer E. Muramyl peptides: immunomodulators, sleep factors, and vitamins. Med Res Rev. 1984;4:111–152. - PubMed
    1. Click RE, Benck L, Alter BJ. Immune response in vitro: I. Culture conditions for antibody synthesis. Cell Immunol. 1972;3:264–276. - PubMed
    1. Damais C, Riveau G, Parant M, Gerota J, Chedid L. Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol. 1982;4:451–462. - PubMed
    1. Dunn TB, Patter MJ. A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst. 1957;18:587–601. - PubMed
    1. Galelli A, Chedid L. Modulation of myelopoiesis in vivo by synthetic adjuvant-active muramyl peptides: induction of colony-stimulating activity and stimulation of stem cell proliferation. Infect Immun. 1983;42:1081–1085. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources